CA-MYTHICAL-GAMES
25.1.2023 13:01:43 CET | Business Wire | Press release
Mythical Games, the next-generation gaming technology studio, has launched Mythical Marketplace 2.0 following the acquisition of marketplace tech start-up DMarket, as part of its continued commitment to innovation in gaming. The new marketplace is built on Mythical’s new layer 1 EVM blockchain and powered by the Mythos native ecosystem token, MYTH. The acquisition is a significant milestone for Mythical Games, with DMarket’s tech facilitating the most advanced trading platform for digital assets. It makes Mythical the world’s second-largest processor of digital assets on a distributed ledger after the Ethereum mainnet, as of December.
Mythical’s Marketplace 2.0 has fully integrated DMarket’s technology to feature principles of its blended payment gateway, featuring a powerful AML and anti-fraud protection system built on more than a decade of industry experience. Combined with Mythical’s expertise in gaming and digital assets, Marketplace 2.0 provides a frictionless user experience that enables peer-to-peer transactions and empowerment for gamers looking to participate in the play-and-own gaming economies of the future. The Mythical Chain has been live for six weeks, processing over 2 million transactions.
“We founded Mythical Games in 2018 with the idea of ushering in both the next generation of gaming and the next generation of gamers. Half a decade later, we’re continuing to do just that. Mythical’s Marketplace 2.0 was designed to not only enhance our platform but, more importantly, improve the player experience and set the standard for the future of gaming,” said John Linden, co-founder and CEO, Mythical Games. “All too often, developers tout features as ‘seamless’ and ‘integrated’ when discussing gaming or metaverse projects. In reality, these solutions are still very complicated and not made for gamers. But with these monumental steps forward, Mythical will provide users with an experience that delivers on both.”
Marketplace 2.0 will support NFL Rivals and Nitro Nation World Tour assets, with plans to expand to all Mythical titles on the Mythical Chain. Assets on the Mythical Chain will be entirely governed by smart contracts with both ownership and commerce logic enforced on a secure distributed digital ledger.
“The new horizons of the gaming space have always been the main focus for DMarket. We’re excited to become a part of Mythical Games' work to reduce barriers to entry for innovative game developers and thriving new economies,” said Vlad Panchenko, co-founder and CEO of DMarket. “We share a vision of how the industry will evolve and how we all can contribute and bring more fun to the gaming community worldwide.”
DMarket’s office in Kyiv, Ukraine, becomes part of Mythical East, with its headquarters in Lisbon, Portugal. Its co-founders, Vlad Panchenko and Tamara Slanova, will become part of Mythical’s Executive leadership team, with a particular focus on building the best and easiest marketplace technology for the gaming industry.
DMarket has also adopted the Mythical Chain for its existing marketplace, which will continue to operate outside of the Mythical Marketplace. DMarket.com will retain the familiar experience with purchases in USD in the web experience; however, all trades are recorded on the Mythical Chain to provide full transparency to the community.
For more information on Mythical Games’ Marketplace 2.0, visit http://mythical.market.
About Mythical Platform
Mythical Platform can be added to pre-existing game economies or built into the design of a new game from the ground up, and enables management of digital asset trades, payments, users, and inventory management, making it possible for buyers and sellers of digital assets to transact confidently in an environment founded on transparency, security, trust and value. Mythical Marketplace provides seamless integration to game inventory and offers fraud protection, fee optimization, and soon asset bundling and buyer and seller pricing recommendations. Mythical partners will also have access to proprietary intelligence, market design and market intervention tools that enable easy and safe digital asset transactions.
About Mythical Games
Acknowledged by Forbes’ Disruptive Technology Companies to Watch in 2019 and Fast Company’s World Changing Ideas 2021, Mythical is a next-generation games technology company creating a gaming ecosystem by leveraging tradeable digital assets for tools that enable players, creators, artists, brands and game developers to become stakeholders and owners in new creator-focused game economies.
Led by gaming industry veterans, the team specializes in building games around player-owned economies and has helped develop major franchises, including Call of Duty, World of Warcraft, Guitar Hero, DJ Hero, Marvel Strike Force and Skylanders.
About DMarket
DMarket is the biggest marketplace for trading gaming and esports digital assets. Based on the Newzoo report, it is also one of the top three blockchain-based marketplaces worldwide. The company was founded in 2017 by serial entrepreneurs Vlad Panchenko and Tamara Slanova. DMarket's partners and customers include Darewise, GSC Game World, the Na’Vi esports team, Unity, Xsolla, and others.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124006123/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom